Application value of Helicobacter pylori, PG and G17 in diagnosing precancerous lesions of gastric cancer

doi:10.3969/j.issn.1004-583X.2021.03.009

Abstract

Abstract:

Objective To explore the correlation among Helicobacter pylori(H.pylori), pepsinogen(PG), and gastrin 17(G17) in precancerous lesions of gastric cancer(PLGC). Methods 856 patients who underwent gastroscopy in our hospital were selectively divided into the case group (n=471, patients with PLGC detected by the pathology) and the control group (n=385, patients with no PLGC detected by the pathology). In the case group, patients were assigned into the chronic atrophic gastritis (CAG) group (n=157), the intestinal metaplasia (IM) group (n=153), the low-grade intraepithelial neoplasia(LGIN) group (n=82), and the high-grade intraepithelial neoplasia(HGIN) group (n=79). The H.pylori infection type and the PG and G17 levels were detected in each group. Results The rate of H.pylori infection type I in the CAG group was higher than that of the control group (P<0.05). PGⅠ in the CAG group was lower than that of the control group (P<0.05). PGⅡ in the IM group, LGIN group and the HGIN group were higher than those of the control group (P<0.05). PGⅠ/PGⅡ(PGR) in the CAG group, the IM group, the LGIN group and the HGIN group were lower than those of the control group (P<0.05). G17 in the LGIN group and the HGIN group were higher than that of the control group (P<0.05). PGⅠ, PGⅡ, and G17 were positively correlated with the positive H.pylori infection. PGR level was negatively correlated with the positive H.pylori infection (P<0.05). Conclusion The H.pylori infection type and the levels of PG and G17 are closely related to PLGC. Detecting of the H.pylori infection type, PG and G17 is of great value for early screening of PLGC.

Key words: helicobacter pylori, pepsinogen, gastrin, gastric neoplasms, precancerous lesions

CLC Number:

R735.2

Jin Ying, Wang Pai, Feng Shibing. Application value of Helicobacter pylori, PG and G17 in diagnosing precancerous lesions of gastric cancer[J]. Clinical Focus, 2021, 36(3): 233-237.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.03.009

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I3/233

Figures/Tables 4

References 21

[1]	Karkhah A, Ebrahimpour S, Rostamtabar M, et al. Helicobacter pylori evasion strategies of the host innate and adaptive immune responses to survive and develop gastrointestinal diseases[J]. Microbiol Res, 2019,218:49-57. doi: 10.1016/j.micres.2018.09.011 pmid: WOS:000456897900006
[2]	申星杰, 刘亮, 朱靖宇. 胃早癌患者内镜治疗前后血清胃蛋白酶原水平的变化和意义[J]. 医学与哲学, 2017,38(4):52-54.
[3]	Loong TH, Soon NC, Nik Mahmud NRK, et al. Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus[J]. Biomed Rep, 2017,7(5):460-468. doi: 10.3892/br.2017.985 pmid: 29181158
[4]	罗伟, 朱志超, 徐宝宏, 等. 唾液幽门螺杆菌检测在胃癌发生发展中的价值[J]. 中国医药导报, 2018,15(22):88-91.
[5]	杨振威, 庄坤, 左利平, 等. 血清PG、G17与Hp对胃癌前病变患者的诊断效果研究[J]. 实用癌症杂志, 2019,34(4):633-636.
[6]	Liu X, He B S, Lin K, et al. Research progression on association of Helicobactor pylori genotype with stomach disease[J]. Progress in Modern Biomedicine, 2016,16(7):1390-1393.
[7]	消化道上皮性肿瘤新国际分类 (维也纳分类)[J]. 胃肠病学, 2000,5(2):135-136.
[8]	谢燕, 文剑波, 李兴. 早期胃癌及癌前病变筛查诊断方案的研究进展[J]. 中国实用医药, 2018,13(11):193-195.
[9]	杜奕奇, 蔡全才, 廖专, 等. 中国早期胃癌筛查流程专家共识意见 (草案)(2017年, 上海)[J]. 胃肠病学, 2018,23(2):92-97.
[10]	徐文娇, 黄雨梅, 钟晓琳, 等. 等量幽门螺杆菌不同灌胃方法对小鼠胃黏膜的影响[J]. 中南大学学报(医学版), 2019,44(6):628-633.
[11]	杨波, 杜利君, 魏剑林, 等. 幽门螺杆菌细胞毒素相关蛋白A、热休克蛋白60和细胞空泡毒素与慢性胃炎患者胃黏膜病理变化的关系[J]. 解放军预防医学杂志, 2018,36(7):832-835.
[12]	张苗苗, 赵志鹏, 李晓晨, 等. 幽门螺杆菌抗体分型检测及分型与胃部疾病的相关性分析[J]. 标记免疫分析与临床, 2020,27(8):1305-1309.
[13]	Tong Y, Wu Y, Song Z, et al. The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical research[J]. BMC Gastroenterol, 2017,17(1):88. doi: 10.1186/s12876-017-0641-6 URL
[14]	Massarrat S, Haj-sheykholeslami A. Increased Serum pepsinogen Ⅱ level as a marker of pangastritis and corpus-predominant gastritis in gastric cancer prevention[J]. Arch Iran Med, 2016,19(2):137-140. doi: 0161902/AIM.0012 pmid: 26838085
[15]	Kumar S, Kumari N, Mittal RD, et al. Pepsinogen-Ⅱ 100 bp ins/del gene polymorphism and its elevated circulating levels are associated with gastric cancer,particularly with Helicobacter pylori infection and intestinal metaplasia[J]. Gastric Cancer, 2016,19(3):808-816. doi: 10.1007/s10120-015-0550-8 URL
[16]	Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis[J]. Aliment Pharmacol Ther, 2017,46(7):657-667. doi: 10.1111/apt.14248 URL
[17]	Zhao WX, Liu ZF, Li XL, et al. Correlations of serum homocysteine, VEGF and gastrin 17 with gastric cancer and precancerous lesions[J]. Eur Rev Med Pharmacol Sci, 2019,23(10):4192-4198. doi: 17922 pmid: 31173290
[18]	Strong VE. Progress in gastric cancer[J]. Updates Surg, 2018,70(2):157-159. doi: 10.1007/s13304-018-0543-3 URL
[19]	王春芳, 刘兵, 孙光, 等. 血清胃蛋白酶原、胃泌素17及幽门螺杆菌对老年胃癌前病变诊断的价值研究[J]. 肿瘤药学, 2018,8(4):588-592.
[20]	De Re V, Orzes E, Canzonieri V, et al. Pepsinogens to distinguish patients with gastric intestinal metaplasia and Helicobacter pylori infection among populations at risk for gastric cancer[J]. Clin Transl Gastroenterol, 2016,7(7):e183. doi: 10.1038/ctg.2016.42 URL
[21]	Al-Ezzy AI. Immunomodulatory effect of H.pylori cag A genotype and gastric hormones on gastric versus inflammatory cells fas gene expression in Iraqi patients with gastroduodenal disorders[J]. Open Access Maced J Med Sci, 2016,4(3):364-373. doi: 10.3889/oamjms.2016.032 URL

组别	例数	性别[例(%)]		年龄(岁)	吸烟史[例(%)]	饮酒史[例(%)]
组别	例数	男	女	年龄(岁)	吸烟史[例(%)]	饮酒史[例(%)]
对照组	385	257(66.75)	128(33.25)	43.72±4.52	188(48.83)	134(34.81)
CAG组	157	66(42.04)^a	91(57.96)	44.25±4.96	79(50.32)	41(26.11)
IM组	153	74(48.37)^a	79(51.63)	49.96±5.64^ab	81(52.94)	42(27.45)
LGIN组	82	43(52.44)^a	39(47.56)	50.13±5.82^ab	45(54.88)	29(35.37)
HGIN组	79	41(51.90)^a	38(48.10)	50.75±5.23^ab	42(53.16)	31(39.24)
统计值		17.293	14.923	0.822	1.185	17.293
P值		<0.01	<0.01	0.623	0.492	<0.01

组别	例数	性别[例(%)]		年龄(岁)	吸烟史[例(%)]	饮酒史[例(%)]
组别	例数	男	女	年龄(岁)	吸烟史[例(%)]	饮酒史[例(%)]
对照组	385	257(66.75)	128(33.25)	43.72±4.52	188(48.83)	134(34.81)
CAG组	157	66(42.04)^a	91(57.96)	44.25±4.96	79(50.32)	41(26.11)
IM组	153	74(48.37)^a	79(51.63)	49.96±5.64^ab	81(52.94)	42(27.45)
LGIN组	82	43(52.44)^a	39(47.56)	50.13±5.82^ab	45(54.88)	29(35.37)
HGIN组	79	41(51.90)^a	38(48.10)	50.75±5.23^ab	42(53.16)	31(39.24)
统计值		17.293	14.923	0.822	1.185	17.293
P值		<0.01	<0.01	0.623	0.492	<0.01

组别	例数	感染率	H.pylori
组别	例数	感染率	Ⅰ型感染	Ⅱ型感染
对照组	385	187(48.57)	146(78.07)	41(21.93)
CAG组	157	84(53.50)	80(95.24)^a	4(4.76)
IM组	153	77(50.33)	67(87.01)	10(12.99)
LGIN组	82	43(52.44)	38(88.37)	5(11.63)
HGIN组	79	41(51.90)	37(90.24)	4(9.76)
χ²值	1.034	3.346	0.924	1.034
P值	0.521	0.013	0.583	0.521

组别	例数	感染率	H.pylori
组别	例数	感染率	Ⅰ型感染	Ⅱ型感染
对照组	385	187(48.57)	146(78.07)	41(21.93)
CAG组	157	84(53.50)	80(95.24)^a	4(4.76)
IM组	153	77(50.33)	67(87.01)	10(12.99)
LGIN组	82	43(52.44)	38(88.37)	5(11.63)
HGIN组	79	41(51.90)	37(90.24)	4(9.76)
χ²值	1.034	3.346	0.924	1.034
P值	0.521	0.013	0.583	0.521

组别	例数	PGⅠ(μg/L)	PGⅡ(μg/L)	PGR	G17(pmol/L)
对照组	385	99.84(73.84~134.82)	9.13(5.97~16.89)	9.87(6.92~14.27)	3.57(1.15~8.47)
CAG组	157	79.76(65.72~108.78)^a	7.78(5.17~19.74)	9.13(5.42~13.27)^a	3.34(1.25~10.89)
IM组	153	97.69(71.48~133.89)	10.42(6.13~17.33)^ab	8.84(6.27~13.82)^ab	3.27(1.47~9.75)
LGIN组	82	104.87(74.79~157.25)	11.94(6.75~17.98)^abc	8.54(6.15~13.78)^abc	4.72(1.04~8.83)^abc
HGIN组	79	109.48(87.68~176.90)	19.67(12.68~28.95)^abcd	8.03(5.12~13.72)^abcd	11.12(1.42~15.82)^abcd
Z值		3.644	15.923	17.724	11.383
P值		0.029	<0.01	<0.01	<0.01